Business Wire

World Sickle Cell Day 2020: Novartis Takes Further Steps to Make Sickle Cell Disease a Healthcare Priority in Europe



Many patients with SCD only live into their 40s and endure unpredictable pain crises which disrupt their lives physically, socially and emotionally.1 It is a genetic condition which is life-long and rising across Europe.2 Despite the World Health Organization recognising SCD as a global problem, knowledge about SCD among healthcare providers and the public is poor.3 SCD remains an invisible health issue in Europe and Novartis is dedicated to help make SCD a healthcare priority in Europe.

“SCD is a neglected chronic disease of increasing global health importance. There is a lot of work to be done to help the growing numbers of patients in Europe,” Professor Béatrice Gulbis, Co-coordinator of the European Reference Network EUROBLOODNET and specialist of inherited rare anemias. “It is important for healthcare professionals, policymakers, patients and the public-at-large to understand the severity of sickle cell disease and take a European-wide collaborative action on education, funding for research and awareness, and guidance and tools for screening and follow-up.”

SCD is a genetic blood disorders affecting millions of people worldwide. 4 It is a life-long and debilitating disease.5 It also has a substantial impact on patients’ emotional well-being and daily life affecting their ability to work and complete education.6 SCD financially affects the individual and their family; society and healthcare systems. 7 The burden of blood disorders in Europe is €23 billion per year, a level of cost that is not matched in current European haematology research funding.7

Early diagnosis and regular medical care can prevent complications and contribute to improved life expectancy and quality of life, however, a recent survey revealed that many patients don’t seek care despite symptoms and complications due to previous poor experience at hospital (39%) with some reporting that healthcare providers do not understand the disease (26%).6,8 Novartis is calling for a European-wide collaborative action on education, funding for research and awareness; and make sure that the patients receive equal and homogeneous healthcare access and treatment across Europe .

Tomorrow, a panel of EU experts and patients will be coming together for a one-hour webinar to highlight the lack of awareness and mis-conceptions of SCD amongst policy makers and the public in Europe. The meeting aims to highlight the action required to help improve the lives of those living with this debilitating disease. The experts will explore:

  • SCD and the complexity of its diagnosis and management
  • The burden of SCD on quality of life for patients and caregivers
  • The impact of the COVID-19 pandemic on existing and emerging rare diseases in Europe
  • Why there is a need for urgent strategy to address equal access to treatment in Europe

The expert panel comprises:

  • Miriam Santos Freire, Patient Advocate
  • Mariane De Montalembert, Healthcare Professional – (Eurobloodnet, ERN)
  • Simone Boselli, Public Affairs Director – (European Organisation for Rare Diseases, EURORDIS)
  • Yolande Adjibi, Head of Patient Relations in Sickle Cell Disease – (Novartis, Region Europe)

Yolande Adjibi, Head of Patient Relations in Sickle Cell Disease at Novartis comments: “For over 40 years, Novartis has been committed to understanding SCD and working towards treatment. We aim to support patients, healthcare providers and caregivers in their experiences with this debilitating disease. However, more needs to be done. We need to start conversations which will spark a positive change for SCD patients.”

In 2016 The European Hematology Association identified a need to improve treatment strategies for both acute and chronic complications of SCD to optimise patient care, in order to positively affect patient health and quality of life, and to reduce hospitalisation length, patient disability, and cost of care but limited progress has been made.7 As COVID-19 poses an additional threat to the lives of SCD patients and subsequently healthcare systems across Europe, urgent action is required to help improve the lives of those affected by SCD and to guide healthcare systems towards early diagnosis and equal access to treatment.

To join the conversation and pose questions directly to the panel please register here:

- END –

About Sickle Cell Disease

Sickle cell disease is a debilitating inherited genetic blood disorder that affects the shape of the red blood cells and can make blood cells and blood vessels stickier than usual.9,10 When blood cells stick to one another, they can form multicellular adhesion clusters in the bloodstream. These clusters can reduce and block the flow of blood and oxygen, which can cause damage to the blood vessels and lead to acute and chronic complications.6,9 These blockages also can lead to painful crises called VOCs, which are considered the clinical hallmark of the disease and the main reason why patients seek medical care in hospitals.9

About Novartis

Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 105 000 people of more than 140 nationalities work at Novartis around the world. Find out more at


1 Adegbola M, et al. 2012. Voices of adults living with sickle cell disease pain. J Natl Black Nurses Assoc. 23(2), pp.16-23.

2 Roberts I, de Montalambert M. 2007. Sickle Cell disease as a paradigm of immigration haematology: new challenges for hematologists in Europe. Haematologica 92(7)pp.865-71.

3 Mburu, Joy; Odame, I. 2019. Sickle Cell Disease: Reducing the Global Disease Burden. Int J Lab Hematol (41) 1:82-88.

4 Jain D, Lothe A, Roshan C. 2015. Sickle cell disease: current challenges. Journal of Hematology & Thromboembolic Diseases. 10. Doi: 10.4172/2329-8790.1000224.

5 Steinberg M. 1999. Management of sickle cell disease. N Engl J Med. 340(13):1021-1030.

6 Osunkwo I, Andemariam B, Inusa B, et al. Management Strategies and Satisfaction Levels in Patients With Sickle Cell Disease: Interim Results From the International Sickle Cell World Assessment Survey (SWAY). Poster presented at: The American Society of Hematology Annual Meeting; December 7-10, 2019; Orlando, FL.

7 European Hematology Association (EHA) Roadmap for European Hematology Research: A Consensus Document (2016), Available at: (Accessed June 2020).

8 National Heart, Lung and Blood Institute. Sickle Cell Disease. Available at: (Accessed June 2020).

9 Gutsaeva D, Parkerson J, Yerigenahally S, et al. 2011. Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for Sickle Cell Disease. 13;17(2), pp.727-35.

10 Sparkenbaugh E, Pawlinski R. 2013. Interplay between coagulation and vascular inflammation in sickle cell disease. Br J Haematol. 162(1). Pp.2-14.

Contact information

For further information please contact:
Yolande Adjibi
Head of Patient Relations in Sickle Cell Disease, Novartis, Region Europe
Tel: +33155476000

Laura Mckinlay
Senior Account Director
Tel: +44 (0)7376 802 980

About Business Wire

Business Wire
Business Wire

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Axway named a Leader in Gartner 2020 Magic Quadrant for Full Life Cycle API Management. For the fifth time.29.9.2020 03:05:00 CESTPress release

Axway (Euronext: AXW.PA), a leading provider of API Management and integration software, today announced it has been positioned by Gartner in the Leaders quadrant of the Gartner 2020 Magic Quadrant for Full Life Cycle API Management.¹ This is the fifth time Axway has been positioned as a Leader. “When it came to the quality of their support and strategic partnership, Axway really stood out from the crowd,” said Chris Hengst, Lead API Architect/API Evangelist, HM Health Solutions. “As well as satisfying all our core technical criteria around API governance, discovery and developer self-service, Axway went above and beyond to help us succeed.” “We believe this evaluation validates the importance of an open API platform like AMPLIFY to help companies create new customer, partner, and employee experiences that drive business growth,” said Patrick Donovan, Axway CEO. “This announcement comes on the heels of Axway being named a Leader in The Forrester Wave™: API Management Solutions Q3 2020.

Epic Fantasy 3DMMORPG Forsaken World: Gods and Demons Open for Pre-registration Today28.9.2020 15:00:00 CESTPress release

Forsaken World: Gods and Demons is an open-world fantasy MMORPG on an incredible scale. Dive into a world of never-ending adventure where treasure and glory awaits the victor. Raid a dragon's lair, search for lost artifacts, or kick back, relax and catch some fish in between epic adventures. The world around you will be influenced by your in-game decisions, with a storyline that allows you to determine the future of Calindor. Leave your mark and become a legend! This press release features multimedia. View the full release here: Pre-register now on the App Store and Google Play (Graphic: Business Wire) Endless Character Customization Change your class at any time and specialize your character just the way you want it. Mix and match abilities and talents to fit your combat style, and customize your appearance to bring out the true you, right down to the facial expression. No two players are the same in FW: GD. A Stunning World Im

Rimini Street Celebrates 15 Years of Delivering Client Success28.9.2020 15:00:00 CESTPress release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of business software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that September marks the 15th anniversary of the Company’s founding in 2005 to redefine the enterprise software support market. The Company set out to deliver a premium, ultra-responsive support model, and bring choice and value to software licensees around the world. Since its inception, Rimini Street has continually set the premium standard on what Oracle and SAP licensees should expect from their support experience. The Company is responsible for delivering a long history of innovative “firsts” for the enterprise software support market, including guaranteed ultra-responsive SLA’s, support for customizations at no additional cost, support for at least 15 years without required upgrades or updates and saving clients nearly $5 billion in total maintenance and support cos

Hyprevention Raises New Financing to Commercialize Spinal Implant Product V-STRUT© in the USA.28.9.2020 14:55:00 CESTPress release

Hyprevention has raised new financing to support the V-STRUT© Vertebral Implant product. The financing will be used to execute the commercialization plans for the US spinal fracture market. The V-STRUT© Vertebral Implant is indicated for use in the treatment of vertebral fractures. In May 2019, a US patent was granted for V-STRUT© and in March 2020, the device received FDA-510(k) clearance. “We are delighted that our existing investors have shown confidence in our product development efforts and commercialization plans for the US market by increasing their investment in the company,” says Cecile Vienney, CEO. The Hyprevention team has entered into a commercial relationship with DAWA Medical and has received several orders for the product from enthusiastic customers. DAWA Medical, a regional distributor of medical products, will promote sales in Florida, Illinois, Texas and Oklahoma. In addition to DAWA the company is in discussion with other commercial partners to bring the innovative

Mavenir acquires ip.access to expand OpenRAN radio portfolio for CSPs and Enterprise Private Networks28.9.2020 14:00:00 CESTPress release

Mavenir, a leading provider of end-to-end cloud-native Network Software Provider for Communications Service Providers (CSPs) announces today that it has acquired ip.access Ltd, a leading 2G, 3G, 4G and 5G-ready small cell solutions provider. This acquisition extends Mavenir’s leadership in OpenRAN radio on three fronts: Communication Service Providers: Adding 2G and 3G capabilities to the OpenRAN portfolio Enterprise: Adding a full suite of enterprise radio solutions for Mavenir’s Private Network offerings, including OnGo/CBRS certified solutions Nontraditional Networks: Leveraging market leading software defined vRAN solutions for Aviation, Maritime, Rural and Remote networks with next generation solutions in the air, on land and at sea. “Operators are looking to transform their 2G/3G networks as they migrate to 4G and 5G,” said Pardeep Kohli, President and CEO, Mavenir. “We expect to provide a seamless, multi radio access technology single RAN offering for those operators that allows

PCI Pharma Services Introduces First-of-its-Kind Digital Platform to Provide Clients with Real-Time Supply Chain Data and Analytics28.9.2020 12:00:00 CESTPress release

PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider today announced the launch of pci | bridge, an innovative digital platform that will give customers immediate visibility into their clinical and commercial supply chain, and provide instantaneous data and insights to inform decision-making. Created using an agile development process whereby key clients collaborated and provided input, PCI built an industry-leading digital interface that delivers greater transparency to clients – saving time and resources to ultimately help bring life-changing therapies to patients faster. The launch of pci | bridge is one of many initiatives that PCI has undertaken to incorporate digital transformation as core to its business strategy. This press release features multimedia. View the full release here: pci | bridge digital platform logo (Photo: Business Wire) “At PCI, we are always loo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom